Jeevan Scientific Technology Ltd (JSTL) Fair Value & Analysis
Healthcare · IN · Market cap ₹1.6B
Fair value as of: Aug 13, 2026
From 12 valuation models · updated 6 days ago
A solid business, but screening 87% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (₹12.28). The favourable scenario is already priced in.
- Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹33.91 – ₹222.75 · fair‑value band ₹7.37 – ₹12.28 · the ₹74.25 price screens above the ₹9.82 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Jeevan Scientific Technology Ltd (JSTL) currently trades at ₹74.25, while our model-based Fair Value estimate is ₹9.82, implying the stock looks roughly 86.8% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).
Over the trailing twelve months, Jeevan Scientific Technology Ltd generated revenue of ₹615M at a net margin of 1.9%. Revenue grew 111.6% year over year. It earns a return on equity of 1.7%. Net debt stands at ₹76.5M. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹7.37 (bear case) to ₹12.28 (bull case); at ₹74.25, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 126% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -64% fair-value upside, at -87%, JSTL screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: Asset-Based (₹24.20) versus Earnings-Based (₹4.80). Highest evidence: ROIC Compounder (72).
Notify me when JSTL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 51 · Market factors (momentum, volatility) 68
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and bio-statistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, …
Full company description
Jeevan Scientific Technology Limited engages in the clinical research and data management businesses in India. The company's services include BA/BE studies that comprise bioanalytical and clinical services, pharmacokinetic and bio-statistics, and glucose clamping; clinical trial services, such as medical writing, clinical trial management and monitoring, drug safety, clinical data management, biostatistics and statistical programming, and quality assurance; and pharmacovigilance services, including ICSR management, aggregate safety reports, risk management plan, signal detection, medical information call center, and other integrated services. It also exports its products. The company was formerly known as Jeevan Softech Limited and changed its name to Jeevan Scientific Technology Limited in March 2011. The company was incorporated in 1999 and is based in Hyderabad, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Jeevan Scientific Technology Ltd reported revenue of ₹615M in FY2025 versus ₹1.5T in FY2021, a compound −85.7%/yr. Reported net income was ₹11.5M in FY2025, compounding −91.4%/yr from FY2021.
JSTL screens 87% overvalued. Compare with Veeva Systems Inc →
Peer Group
Health Information Services · 129 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $241.51 | $91.49 | -62% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | -87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | -64% |
| HealthEquity, Inc HQY | $105.50 | $56.63 | -46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | -72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | -69% |
| Waystar Holding WAY | $24.54 | $12.86 | -48% |
| XtalPi Holdings 2228 | HK$8.19 | HK$1.04 | -87% |
| Doximity, Inc DOCS | $24.99 | $25.91 | +4% |
| Privia Health Group PRVA | $21.54 | $5.26 | -76% |
Compare Jeevan Scientific Technology Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Jeevan Scientific Technology Ltd (JSTL) overvalued or undervalued?
What is the fair value of JSTL?
What is the quality score of JSTL?
What is the revenue of Jeevan Scientific Technology Ltd (JSTL)?
What is the net profit margin of JSTL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Jeevan Scientific Technology Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.